Primary Peptides
Primary Peptides is a pioneering biotechnology company focused on developing new therapeutics for neurological diseases through innovative protein manipulation technologies. Their mission is to create effective treatments for serious neurological disorders by expanding the scope of drug targets using protein-protein interaction blockade, protein degradation, and molecular glues. They aim to address unmet medical needs with a platform that includes clinical-stage assets targeting neuroprotection, Parkinson's disease, ALS, and stroke-related gene therapy.
Industries
Nr. of Employees
small (1-50)
Primary Peptides
Unit F142, 2211 Wesbrook Mall, Vancouver BC V6T 2B5, Canada
Products
Clinical-stage peptide therapeutic for neuroprotection in stroke
A peptide therapeutic advanced to clinical-stage development aiming to provide neuroprotection following stroke.
Preclinical alpha-synuclein targeting peptide (Parkinson's disease)
Peptide candidate designed to knock down alpha-synuclein, prepared to enter IND-enabling studies; supported by published preclinical data.
Preclinical TDP-43 targeting peptide (ALS)
Peptide therapeutic candidate targeting TDP-43 prepared to enter IND-enabling studies for amyotrophic lateral sclerosis (ALS).
Stroke-triggered gene vector for inducible peptide release (discovery)
Discovery-stage gene vector designed to release a therapeutic peptide upon occurrence of a stroke event.
Clinical-stage peptide therapeutic for neuroprotection in stroke
A peptide therapeutic advanced to clinical-stage development aiming to provide neuroprotection following stroke.
Preclinical alpha-synuclein targeting peptide (Parkinson's disease)
Peptide candidate designed to knock down alpha-synuclein, prepared to enter IND-enabling studies; supported by published preclinical data.
Preclinical TDP-43 targeting peptide (ALS)
Peptide therapeutic candidate targeting TDP-43 prepared to enter IND-enabling studies for amyotrophic lateral sclerosis (ALS).
Stroke-triggered gene vector for inducible peptide release (discovery)
Discovery-stage gene vector designed to release a therapeutic peptide upon occurrence of a stroke event.
Services
Engagements for partnerships or licensing to develop or commercialize peptide-based therapeutics; page indicates intent to pursue collaborations.
Engagements for partnerships or licensing to develop or commercialize peptide-based therapeutics; page indicates intent to pursue collaborations.
Expertise Areas
- Peptide therapeutics
- Targeted protein degradation
- Protein–protein interaction inhibition
- Neuroscience and CNS drug development
Key Technologies
- Peptide-based inhibitors of protein–protein interactions
- Chaperone-mediated autophagy-targeting peptide degradation (lysosomal/proteasomal)
- Peptide molecular glues (bifunctional peptide constructs)
- Cell-penetrating peptide domains with BBB permeability
News & Updates
Critical Role of Increased PTEN Nuclear Translocation in Excitotoxic and Ischemic Neuronal Injuries.
Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation.
Palmitoyl acyltransferase zD17 mediates neuronal responses in acute ischemic brain injury by regulating JNK activation in a signaling module.
Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.
Critical Role of Increased PTEN Nuclear Translocation in Excitotoxic and Ischemic Neuronal Injuries.
Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation.
Palmitoyl acyltransferase zD17 mediates neuronal responses in acute ischemic brain injury by regulating JNK activation in a signaling module.
Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.